Missy McKean-Matthews
Overview
Explore the profile of Missy McKean-Matthews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
21
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gottlieb A, Armstrong A, Blauvelt A, Griffiths C, Pinter A, Gooderham M, et al.
J Drugs Dermatol
. 2024 Aug;
23(8):619-625.
PMID: 39093657
Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outcomes. Objective: To assess clear responses...
2.
Egeberg A, Hawkes J, Somani N, Burge R, See K, Gallo G, et al.
Dermatol Ther (Heidelb)
. 2024 Apr;
14(4):1007-1018.
PMID: 38647975
Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat with...
3.
Elewski B, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, et al.
Dermatol Ther (Heidelb)
. 2022 Mar;
12(4):911-920.
PMID: 35279805
Introduction: The lifetime incidence of nail psoriasis in patients with psoriasis is 80-90%, with 23-27% of patients having nail psoriasis at any given time. Nail psoriasis is even more prevalent...
4.
Augustin M, Gallo G, See K, McKean-Matthews M, Burge R, Gooderham M, et al.
J Drugs Dermatol
. 2022 Feb;
21(2):122-126.
PMID: 35133112
Background: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy. Objective: To determine early treatment response rates to...
5.
Papp K, Gerdes S, Leonardi C, Elmaraghy H, See K, McKean-Matthews M, et al.
J Drugs Dermatol
. 2021 Aug;
20(8):880-887.
PMID: 34397207
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoriasis were assessed. Methods: Patients...
6.
Hawkes J, See K, Burge R, Strakbein S, McKean-Matthews M, Saure D, et al.
Dermatol Ther (Heidelb)
. 2021 May;
11(4):1107-1118.
PMID: 34050899
Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex...
7.
Leonardi C, See K, Gallo G, McKean-Matthews M, Zhang Y, Goldblum O, et al.
Dermatol Ther (Heidelb)
. 2021 May;
11(4):1249-1263.
PMID: 34047947
Introduction: Psoriasis Area Severity Index (PASI) assessment is complex and time-consuming. A simpler assessment measure more sensitive to changes in symptom severity and predictive of patients' quality of life (Dermatology...
8.
Gooderham M, Elewski B, Augustin M, Iversen L, Torii H, Burge R, et al.
J Drugs Dermatol
. 2021 Apr;
20(4):394-401.
PMID: 33852247
Objective: We describe patient-reported outcomes and quality of life through 5 years of treatment in patients with moderate-to-severe plaque psoriasis in the UNCOVER-1 and -2 studies. Methods: This analysis included...
9.
Zachariae C, Gordon K, Kimball A, Lebwohl M, Blauvelt A, Leonardi C, et al.
J Am Acad Dermatol
. 2018 Apr;
79(2):294-301.e6.
PMID: 29653208
Background: Ixekizumab has demonstrated improvement in patients with moderate-to-severe psoriasis by selectively targeting interleukin-17A, which is a proinflammatory cytokine that is important in the pathogenesis of psoriasis. Objective: To report...